We lower patient costs. We compensate providers for high quality care.

Our approach to positive behavior change is backed by rigorous research.

Private pharmacies and clinics play a pivotal role in Africa. This presents an opportunity with unique challenges.


The private sector is vast but fragmented.

Maisha Meds’ software consolidates data from private pharmacies and clinics across the region.

This quality and cost of care are inconsistent. Plus, thousands of health care providers are out of reach to funders and governments.


The vast majority are uninsured.

Maisha Meds enrolls patients for discounted care, similar to health insurance. We also offer pharmacies weekly deliveries of vetted medicines.

Yet, people turn to the private sector over public systems because it’s fast, convenient, and consistently has essential products in stock.


People can’t afford the most effective care.

Maisha Meds uses global health funds to lower out-of-pocket costs, ensuring that the best options are ones patients can afford.

Patients often buy malaria drugs without testing first, choose less effective contraceptives, and take partial doses to save on costs.


The health burden is undeniable.

Maisha Meds rewards providers and empowers patients to follow clinical guidelines.

This improves health outcomes, cost-effectiveness, and data reporting.

Ineffective care can lead to poor health outcomes, drug resistance, and unintended pregnancy.


The Provider

I use the app to run my business by making sales and tracking inventory

I get reimbursed for following guidelines like testing for malaria before treatment

The Patient

I enroll in the program by verifying my identity using USSD or an ID

I access subsidized care for malaria, family planning, and HIV prevention

The Partner

My funds reach providers and patients to improve care in the private sector

I use pharmacy data to help design programs and direct funds where they’re needed



Our program more than quadrupled the rate at which providers followed malaria testing and treatment guidelines in Kenya. Importantly, there was a drop in antimalarial use when people tested negative in this study.

Data from over 50,000 patients buying malaria products, June '21 – Feb '22. Source: Dieci, Gertler, Kolstad. Working Paper, 2023

Family Planning

Women opted for long-acting contraception nearly 6 times more often when we subsidized the cost through our app. Our study also found most patients switched from less effective short-term methods like emergency and oral contraceptives.

Data show share of transactions including DMPA-SC. Discount and incentive arms also include free pharmacy supply of DMPA-SC. Source: Dieci, Gertler, Paramo. Working Paper, 2023.